Clinical Epidemiology & Biostatistics



Mark Oremus

BA (McGill), MA (Concordia), MSc (McGill), PhD (McGill)

McLaughlin Foundation Professor of Population and Public Health & Assistant Professor,
Department of Clinical Epidemiology & Biostatistics

Co-Associate Director , McMaster Evidence-based Practice Centre

Associate Scientific Director, Canadian Longitudinal Study on Aging

Career Scientist Award Holder, Ontario Ministry of Health and Long-term Care


905.525.9140 x22437
905.522.7681
oremusm@mcmaster.ca

McMaster University
DTC Building, Room 308
1280 Main Street West
Hamilton, ON, Canada,
L8S 4L8

Office Location: Downtown Centre
50 Main Street East, Room 308
Hamilton, Ontario, Canada, L8N 1E9

Administrative Assistant: Leah Macdonald
905.525.9140 x22882
905.522.7681
lmacdon@mcmaster.ca

Academic Interests

Population and public health, aging, dementia, caregiving, knowledge transfer, questionnaire design and administration, systematic reviews, measuring drug efficacy, health economics, health policy.

Selected Publications


  1. Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011;29(2):141-156.
  2. Oremus M, Santaguida P, Raina P. Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia. Clin Med Insights Ther. 2010;2(1):809-824.
  3. Oremus M, Tarride JE. An economic evaluation of surgery versus collagen injection for the treatment of female stress urinary incontinence. Can J Urol. 2010;17(2):5087-5093.
  4. Oremus M, Raina P, Eva K, Lavis JN, Nair K, Lo A, Smith S.  Impact of clinician judgment on formulary committees' recommendations in Canada. J Health Serv Res Policy. 2010;15(2):98-105.
  5. Oremus M, Tarride JE, Clayton, N, Raina P. Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. BMC Health Serv Res. 2009;9(1):246 - doi:10.1186/1472-6963-9-246.
  6. Oremus M, Tarride JE. A systematic review of the use of contingent valuation in Alzheimer's disease research. Dement Int J Soc Res Pract. 2008;7(4):461-480.
  7. Oremus M. Systematic review of economic evaluations of Alzheimer's disease medications. Expert Rev Pharmacoeconomics Outcomes Res. 2008;8(3):273-289.
  8. Raina P, Santaguida PL, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397.
  9. Oremus M, Wolfson C, Vandal AC, Bergman H. Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer disease. Can J Aging. 2007;26(3):205-212.
  10. Oremus M, Wolfson C, Bergman H, Vandal AC. Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease. Can J Aging. 2007;26(2):139-148.

Search for citations for Dr. Oremus on PubMed